Opko Health Inc (OPK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Opko Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.30 $ — 33% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -7.5%
- Exp. sales growth 3Y > 5% -1.8%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -1.8%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 2
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -84.4%
- ROCE > 15% -12.3%
- Expected return > 10% -21.3%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
NeutralGeprüft am 13.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 26.02.2026) und 2024 (03.03.2025) sowie die vier jüngsten Quartalsberichte (10-Q, bis 31.03.2026). In den ausgewerteten SEC-Filings von OPKO Health findet sich kein wesentlicher KI-Bezug: keine KI-Umsatzquelle (das Geschäft besteht aus Wachstumshormon NGENLA über Pfizer, Rayaldee, der Biotech-Pipeline ModeX sowie dem Labor BioReference), kein dokumentierter operativer KI-Einsatz und kein konkretes KI-Geschäftsrisiko für das eigene Modell. Die einzige Erwähnung von „artificial intelligence“ steht in der Cybersecurity-Darstellung (Item 1C) des 10-K 2025 als generische Floskel, wonach Angreifer KI nutzen könnten, um Cyberattacken wirksamer zu machen — laut Kriterienkatalog kein Bedroht-Beleg (Boilerplate-Risk-Floskel ohne konkreten Bezug zum Geschäftsmodell). Nach der Vorrang-Regel (verkauft > bedroht > nutzt > neutral) bleibt es damit dokumentiert bei „neutral“. Die vier jüngsten 10-Q enthalten gar keine KI-Treffer.
View the full file — quotes, sources, reviewed filings
„Such attacks also may be further enhanced in frequency or effectiveness through threat actors' use of artificial intelligence ("AI")."
Solche Angriffe können zudem in Häufigkeit oder Wirksamkeit durch den Einsatz künstlicher Intelligenz („KI“) durch die Angreifer verstärkt werden.
„As with many innovations, AI presents risks, challenges, and unintended consequences that could affect its adoption, and therefore our business. AI algorithms and training methodologies may be flawed, ineffective or inadequate."
Wie bei vielen Innovationen birgt KI Risiken, Herausforderungen und unbeabsichtigte Folgen, die ihre Verbreitung und damit unser Geschäft beeinflussen könnten. KI-Algorithmen und Trainingsmethoden können fehlerhaft, unwirksam oder unzureichend sein.
Filings Reviewed: 10-Q 2026-04-28 · 10-Q 2025-10-29 · 10-Q 2025-07-31 · 10-Q 2025-05-01 · 10-K 2026-02-26 · 10-K 2025-03-03
Rated on July 13, 2026 · How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -15.5% failed
- More than 10% revenue growth is expected for the coming year 5.6% failed
- Share count grows by less than 3% a year 1.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -46.3% failed
- Gross margin at 40% or higher and without meaningful erosion 21.1% failed
- Goodwill from acquisitions does not grow faster than revenue 25.1% failed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 78 m failed
- Return on capital at 15% or higher, or up versus two years ago -12.3% failed
- Insiders hold at least 10% or are net buyers 49.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 236.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.22 | -0.22 – -0.22 | 566 | – | 1 |
| 12/31/2027 | -0.28 | -0.29 – -0.26 | 585 | -25.0% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.02 | – | 184 | 1.00 | 7.60 | -44 | -50 |
| 2025: Q1 | -0.10 | – | 150 | -13.70 | -45.10 | -35 | -38 |
| 2025: Q2 | -0.19 | – | 157 | -13.90 | -94.70 | -83 | -87 |
| 2025: Q3 | 0.03 | -22.50 | 152 | -12.60 | 14.30 | -35 | -38 |
| 2025: Q4 | -0.04 | -302.00 | 148 | -19.20 | -21.10 | -26 | -29 |
| 2026: Q1 | -0.07 | – | 124 | -17.20 | -44.20 | -19 | -21 |
| 2026: Q2 | -0.01 | 94.70 | 164 | 4.30 | -5.10 | -44 | -44 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,222 | -73 | -48 | -0.10 | 32 | 2,092 | 2,767 |
| 2017 | 966 | -276 | -305 | -0.55 | -92 | 1,844 | 2,590 |
| 2018 | 990 | -171 | -153 | -0.27 | -109 | 1,791 | 2,451 |
| 2019 | 902 | -274 | -315 | -0.53 | -173 | 1,615 | 2,309 |
| 2020 | 1,435 | 58 | 31 | 0.05 | 39 | 1,672 | 2,473 |
| 2021 | 1,775 | 19 | -30 | -0.05 | 38 | 1,685 | 2,400 |
| 2022 | 1,004 | -226 | -328 | -0.46 | -95 | 1,562 | 2,167 |
| 2023 | 864 | -157 | -189 | -0.25 | -28 | 1,389 | 2,012 |
| 2024 | 713 | -152 | -53 | -0.08 | -183 | 1,365 | 2,200 |
| 2025 | 607 | -219 | -226 | -0.30 | -179 | 1,268 | 1,932 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
OPKO Health, Inc. ist ein Gesundheitsunternehmen in den USA, Irland, Chile, Spanien, Israel, Mexiko und international.
| Employees | 2,275 |
|---|---|
| Headquarters | Miami, FL |
| Address | 4400 Biscayne Boulevard, 33137 Miami, United States |
| Phone | 305 575 4100 |
| Website | opko.com |
| IPO Date | 2. Nov 1995 |
| ISIN | US68375N1037 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Phillip Frost M.D., Ph.D. | Chairman of the Board & CEO | 1936 |
| Jane H. Hsiao M.B.A., Ph.D. | Vice Chairman of the Board & Chief Technical Officer | 1947 |
| Elias Adam Zerhouni M.D. | President & Vice Chairman of the Board | 1951 |
| Adam E. Logal | Senior VP, CFO, Chief Accounting Officer & Treasurer | 1978 |
| Steven D. Rubin Esq., J.D. | Executive VP of Administration & Director | 1960 |
| Akhtar Ashfaq FACP, FASN, M.D. | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal | – |
| Gary J. Nabel M.D., Ph.D. | Chief Innovation Officer & Director | 1954 |
| Giovanni Abbadessa M.D., Ph.D. | Chief Medical Officer of ModeX | – |
| John R. Mascola M.D. | Chief Scientific Officer of ModeX | – |
| Gene Yau | Head of Business Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 24. Jul 2026 | Logal Adam | Sr. Vice President, CFO | Other | 53,266 | 1.22 | 64,985 |
| 24. Jul 2026 | Rubin Steven D | Executive VP-Administration | Other | 53,266 | 1.22 | 64,985 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.